Estimating the annual distribution of monarch butterflies in Canada over 16 years using citizen science data

Monarch butterflies (Danaus plexippus, Linnaeus, 1758) are comprised of two migratory populations separated by the Rocky Mountains and are renowned for their long-distance movements among the United States, Canada, and Mexico. Both populations have declined over several decades across North America prompting all three countries to evaluate conservation efforts. Monitoring monarch distribution and abundance is a necessary aspect of ongoing management in Canada where they are a species at risk. We used presence-only data from two citizen science data sets to estimate the annual breeding distribution of monarch butterflies in Canada between 2000 and 2015. Monarch breeding distribution in Canada varied widely among years owing to natural variation, and when considering the upper 95% of the probability of occurrence, the annual mean breeding distribution in Canada was 484 943 km(2) (min: 173 449 km(2); max: 1 425 835 km(2)). The area of occurrence was approximately an order of magnitude larger in eastern Canada than in western Canada. Habitat restoration for monarch butterflies in Canada should prioritize productive habitats in southern Ontario where monarchs occur annually and, therefore, likely contribute most to the long-term viability of monarchs in eastern North America. Overall, our assessment sets the geographic context to develop successful management strategies for monarchs in Canada.Liber Ero Postdoctoral Fellowship; University Research Chair from the University of GuelphOpen access journalThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

Gene expression profiles of 4‐hydroxy‐N‐desmethyl‐tamoxifen (endoxifen)‐ and 4‐hydroxy‐tamoxifen (4OHTAM)‐treated human breast cancer cells determined by CDNA microarray analysis

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109798/1/cptclpt2004192.pd

FlyRNAi.org—the database of the Drosophila RNAi screening center: 2012 update

FlyRNAi (http://www.flyrnai.org), the database and website of the Drosophila RNAi Screening Center (DRSC) at Harvard Medical School, serves a dual role, tracking both production of reagents for RNA interference (RNAi) screening in Drosophila cells and RNAi screen results. The database and website is used as a platform for community availability of protocols, tools, and other resources useful to researchers planning, conducting, analyzing or interpreting the results of Drosophila RNAi screens. Based on our own experience and user feedback, we have made several changes. Specifically, we have restructured the database to accommodate new types of reagents; added information about new RNAi libraries and other reagents; updated the user interface and website; and added new tools of use to the Drosophila community and others. Overall, the result is a more useful, flexible and comprehensive website and database

Menopausal status and estrogen receptor genotypes influenced the severity of hot flashes after tamoxifen treatment

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109844/1/cptclpt200521.pd

Pii‐21

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109873/1/cptclpt2006159.pd

CYP genotypes influence the effect of tamoxifen therapy on serum lipids

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110066/1/cptclpt2004270.pd

Investigation of fundamental ultrasonic propagation characteristics in NDT of electron beam melting additive manufactured samples

New approaches for efficient NDT inspection of modern additively manufactured metallic components are required urgently to qualify and validate the next generation of metallic parts across a range of industries. Ultrasonic testing is a fundamental component of NDT for such additive manufacturing processes. This work studies the ultrasonic propagation characteristics of EBM manufactured sample coupons in Alloy 718 material. Fundamental longitudinal and shear wave velocity measurements are experimentally measured in 3 orthogonal build directions of the sample coupons. Results show a dependency of the ultrasonic velocities and the build direction. The measured velocities are further verified in a phased array measurement showing successful results that highlights the potential of continued studies with synthetic apertures techniques

ER‐alpha and ER‐beta genotypes predict tamoxifen effects on serum lipids in breast cancer patients

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110087/1/cptclpt200418.pd

Estrogen Receptor Genotypes, Menopausal Status, and the Effects of Tamoxifen on Lipid Levels: Revised and Updated Results

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109960/1/cptclpt2010143.pd

Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers

BACKGROUND: Efavirenz exhibits multiple interactions with drug-metabolizing enzymes and transporters, and for this reason efavirenz-based HIV therapy is associated with altered pharmacokinetics of coadministered drugs. Probably by the same mechanism, efavirenz-based HIV therapy affects the disposition of endogenous compounds, but this effect is difficult to directly link with efavirenz because it is used in combination with other drugs. OBJECTIVES: To explore the effect of efavirenz monotherapy on biochemical laboratory values in a clinical trial of healthy volunteers. METHODS: Men and women (aged 18-49 years) with body mass index ≤32 who were assessed to be healthy based on medical history, physical examination, and standard laboratory screening received a single (600 mg) and multiple doses (600 mg/d for 17 days) of efavirenz orally. This trial was designed to determine the pharmacokinetics and drug interactions of efavirenz. As part of this study, analysis of serum chemistries that were measured at study entry (screening) and 1 week after completion of the multiple dose study (exit) is reported. RESULTS: Data from 60 subjects who fully completed and 13 subjects who partially completed the study are presented. Total bilirubin was substantially reduced at exit (by ~30%, with large intersubject variability) compared with screening values (P < 0.0001). The percent changes were in part explained by the intersubject differences in baseline total bilirubin because there was a significant correlation between baseline (screening) values and percent change at exit (r = 0.50; P < 0.0001). Hemoglobin and absolute neutropenia were also substantially decreased at exit compared with screening, but this may be due to intensive blood sampling rather than direct effect of efavirenz on these parameters. No significant correlation was found between percent change in hemoglobin versus percent change in bilirubin, indicating the effect of efavirenz on bilirubin is independent of its effects on hemoglobin. CONCLUSIONS: Efavirenz monotherapy significantly lowers plasma total bilirubin concentration in healthy volunteers independent of its effect on hemoglobin, probably through its effects on bilirubin metabolism and transport (uptake and efflux). These findings help explain reversal by efavirenz of hyperbilirubinemia induction observed by some protease inhibitor antiretroviral drugs (eg, atazanavir). Besides its well-documented role on drug interactions, efavirenz may alter the disposition of endogenous compounds relevant in physiologic homeostasis through its interaction with drug metabolizing enzymes and/or drug transporters. ClinicalTrials.gov identifier: NCT00668395